M&A Deal Summary |
|
|---|---|
| Date | 2010-12-01 |
| Target | Genzyme Genetics |
| Sector | Life Science |
| Buyer(s) | LabCorp |
| Sellers(s) | Genzyme |
| Deal Type | Divestiture |
| Deal Value | 925M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Sector | Test/Measurement Equipment |
| Employees | 67,000 |
| Revenue | 12.2B USD (2023) |
LabCorp of America Holdings is a provider of medical laboratory tests and services through a national network of primary clinical laboratories and specialty testing laboratories. LabCorp is based in Burlington, North Carolina.
| DEAL STATS | # |
|---|---|
| Overall | 15 of 44 |
| Sector (Life Science) | 10 of 21 |
| Type (Divestiture) | 1 of 15 |
| State (Massachusetts) | 1 of 5 |
| Country (United States) | 15 of 42 |
| Year (2010) | 2 of 2 |
| Size (of disclosed) | 3 of 14 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-07-13 |
DCL Medical laboratories
Indianapolis, Indiana, United States DCL Medical laboratories LLC, a women's health-focused laboratory, provides diagnostic and clinical trial testing to physicians, hospitals and pharmaceutical companies throughout the central Midwest. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-06-01 |
Clearstone Central Laboratories
Mississauga, Ontario, Canada Clearstone Central Laboratories, Inc., is a provider of central laboratory services for late-stage clinical trials. |
Buy | - |
Genzyme is a global biotech company. Genzyme's products and services are focused on rare inherited disorders, kidney disease, orthopaedics, cancer, transplant and immune disease. Genzyme was formed in 1981 and is based in Cambridge, Massachusetts.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 3 |
| Sector (Life Science) | 1 of 1 |
| Type (Divestiture) | 2 of 3 |
| State (Massachusetts) | 1 of 1 |
| Country (United States) | 2 of 2 |
| Year (2010) | 2 of 2 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2010-11-18 |
Genzyme ’s Diagnostic Product Division
United States Genzyme Diagnostics is a leading provider of global diagnostic products for diagnostics manufacturers, clinical laboratories and physician offices. Sekisui acquired facilities in the U.S., Canada, Germany and the U.K. |
Sell | $265M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2011-02-10 |
Genzyme Corp -Cholestagel
Ontario, Canada Genzyme Corp -Cholestagel(R) Colesevelam is a bile acid sequestrant administered orally. Cholestagel(R) is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. Cholestagel(R) is contraindicated in patients with bowel or biliary obstruction. Cholestagel(R) is contraindicated in patients with serum triglyceride (TG) > 500 mg/dL and in patients with a history of hypertiglyceridemia-induced pancreatitis. |
Sell | R$2M |
